The Food and Drug Administration (FDA) has approved Tri-Lo-Estarylla (ethinyl estradiol, norgestimate; Sandoz) tablets for oral contraception. Tri-Lo-Estarylla is a therapeutic equivalent of Ortho Tri-Cyclen Lo (Janssen).
Tri-Lo-Estarylla is a progestin and estrogen combination oral contraceptive. Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
Tri-Lo-Estarylla will be available in 0.025mg/0.025mg/0.025mg and 0.18mg/0.215mg/0.25mg strengths in 28-count packs.
For more information call (800) 525-8747 or visit Sandoz.com.